These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25623823)

  • 1. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
    Xu C; Wan X; Xu L; Weng H; Yan M; Miao M; Sun Y; Xu G; Dooley S; Li Y; Yu C
    J Hepatol; 2015 Jun; 62(6):1412-9. PubMed ID: 25623823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.
    Wan X; Xu C; Lin Y; Lu C; Li D; Sang J; He H; Liu X; Li Y; Yu C
    J Hepatol; 2016 Apr; 64(4):925-32. PubMed ID: 26639394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways.
    Lv Y; Gao X; Luo Y; Fan W; Shen T; Ding C; Yao M; Song S; Yan L
    J Nutr Biochem; 2019 Sep; 71():110-121. PubMed ID: 31325892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
    Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
    Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study.
    Xu K; Zhao X; Fu X; Xu K; Li Z; Miao L; Li Y; Cai Z; Qiao L; Bao J
    Biomed Pharmacother; 2019 Sep; 117():109158. PubMed ID: 31252266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The involvement and mechanism of febuxostat in non-alcoholic fatty liver disease cells.
    Tang W; Mu J; Chen QI; Li X; Liu H
    J Biol Regul Homeost Agents; 2018; 32(3):545-551. PubMed ID: 29921379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Accumulation of Hypoxanthine: A Link Between Hyperuricemia and Nonalcoholic Fatty Liver Disease.
    Toledo-Ibelles P; Gutiérrez-Vidal R; Calixto-Tlacomulco S; Delgado-Coello B; Mas-Oliva J
    Arch Med Res; 2021 Oct; 52(7):692-702. PubMed ID: 33966916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation.
    Zhang X; Zhang JH; Chen XY; Hu QH; Wang MX; Jin R; Zhang QY; Wang W; Wang R; Kang LL; Li JS; Li M; Pan Y; Huang JJ; Kong LD
    Antioxid Redox Signal; 2015 Apr; 22(10):848-70. PubMed ID: 25602171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
    Yoon IS; Park DH; Ki SH; Cho SS
    J Pharm Pharmacol; 2016 Dec; 68(12):1597-1603. PubMed ID: 27696407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphenol A promotes hyperuricemia via activating xanthine oxidase.
    Ma L; Hu J; Li J; Yang Y; Zhang L; Zou L; Gao R; Peng C; Wang Y; Luo T; Xiang X; Qing H; Xiao X; Wu C; Wang Z; He JC; Li Q; Yang S
    FASEB J; 2018 Feb; 32(2):1007-1016. PubMed ID: 29042453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.
    Xu C
    Hepatol Int; 2016 Mar; 10(2):286-93. PubMed ID: 26671825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoorientin exerts a urate-lowering effect through inhibition of xanthine oxidase and regulation of the TLR4-NLRP3 inflammasome signaling pathway.
    An MF; Wang MY; Shen C; Sun ZR; Zhao YL; Wang XJ; Sheng J
    J Nat Med; 2021 Jan; 75(1):129-141. PubMed ID: 33188510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
    Kim SM; Lee SH; Kim YG; Kim SY; Seo JW; Choi YW; Kim DJ; Jeong KH; Lee TW; Ihm CG; Won KY; Moon JY
    Am J Physiol Renal Physiol; 2015 May; 308(9):F993-F1003. PubMed ID: 25651569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
    Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
    Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.
    Petta S; Cammà C; Cabibi D; Di Marco V; Craxì A
    Aliment Pharmacol Ther; 2011 Oct; 34(7):757-66. PubMed ID: 21790685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia.
    Xie Z; Luo X; Zou Z; Zhang X; Huang F; Li R; Liao S; Liu Y
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3602-3606. PubMed ID: 28655421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
    Zhu W; Feng PP; He K; Li SW; Gong JP
    Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk for the development of non-alcoholic fatty liver disease: A prospective study.
    Wang J; Ma L; Chen S; Xu L; Miao M; Yu C; Li Y; Xu C
    J Gastroenterol Hepatol; 2018 Aug; 33(8):1518-1523. PubMed ID: 29381226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.
    Yang G; Lee HE; Lee JY
    Sci Rep; 2016 Apr; 6():24399. PubMed ID: 27075683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.